



## **Evolus to Participate in Global Mizuho Investor Conference**

November 26, 2018

**Irvine, Calif., November 26, 2018** – Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced today that members of management will be participating in the Global Mizuho Investor Conference, in New York, NY.

**Event:** Global Mizuho Investor Conference

**Format:** 1x1 Meetings

**Date:** Tuesday, December 4, 2018

**Location:** New York, NY

### **About Evolus, Inc.**

Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus' lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.

### **Evolus Contacts:**

#### **Investors**

Ashwin Agarwal, Evolus

Tel: +1-949-284-4559

Email: [IR@Evolus.com](mailto:IR@Evolus.com)

Brian Johnston, The Ruth Group

Tel: +1 646-536-7028

Email: [IR@Evolus.com](mailto:IR@Evolus.com)

#### **General Media**

Kirsten Thomas, The Ruth Group

Tel: +1-508-280-6592

Email: [kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

#### **Trade Media**

Dani Shaffer, Alison Brod Marketing + Communications

Tel: +1-212-230-1800

Email: [evolus@alisonbrodmc.com](mailto:evolus@alisonbrodmc.com)

###